For Ph-like acute lymphoblastic leukemia (ALL), tyrosine kinase inhibitors (TKIs) may be effective
the ONA take:
According to findings presented at the American Association for Cancer Research special conference Hematologic Malignancies: Translating Discoveries to Novel Therapies in Philadelphia, Pennsylvania, tyrosine kinase inhibitors (TKIs) may be effective for the treatment of children and young adults with Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL).
Kathryn Roberts, PhD, postdoctoral research associate at St. Jude Children's Research Hospital in Memphis, Tennessee, and her colleagues recently described a type of B-cell ALL characterized by tyrosine kinase mutations associated with poor outcomes. This subtype of ALL is termed Ph-like ALL. The researchers introduced genetic mutations to tyrosine kinases in normal mouse blood cells and found that the cells developed Ph-like ALL. Then, the researchers grew human Ph-like ALL tumors in mice and treated them with dasatinib, a TKI, and observed decreased tumor burden in the mice. Furthermore, they found that the signal transducer and activator of transcription (STAT) signaling pathway associated with the genetic alterations involving tyrosine kinases was suppressed.
The researchers suggest that other TKIs approved by the U.S. Food and Drug Administration (FDA), such as crizotinib, imatinib, and ruxolitinib, could possibly be used to treat children and young adults with Ph-like ALL.
TKIs may be effective for the treatment of acute lymphoblastic leukemia.
Tyrosine kinase inhibitors (TKIs) may improve treatment outcome for children and young adults with Ph-like acute lymphoblastic leukemia (Ph-like ALL), a disease with dismal prognosis, according to data presented at the American Association for Cancer Research special conference Hematologic Malignancies: Translating Discoveries to Novel Therapies, held Sept. 20-23.
"We recently described a subtype of B-cell acute lymphoblastic leukemia with very poor outcome that is characterized by genetic alterations involving tyrosine kinases, termed Ph-like ALL," said Kathryn Roberts, PhD, postdoctoral research associate in the Department of Pathology at St. Jude Children's Research Hospital in Memphis, Tennessee. "We wanted to examine whether these alterations contribute to the development of Ph-like ALL, and determine if they could be targeted with tyrosine kinase inhibitors.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|